PLANO, Texas – Pharmaceutical Strategies Group (PSG), a leading pharmacy intelligence and technology company providing innovative drug management solutions to hospitals, health systems, health plans and employers, is celebrating its 25th anniversary.
“Building a company with a 25-year history is not something anyone does alone,” said Dave Borden, CEO. “It takes a team of professionals with character, commitment and competency, and we are incredibly grateful to each of the individuals who have helped shape our company’s past, present and future.”
From its roots as AELRx, a drug cost management consulting company founded in 1994, PSG’s consulting arm has grown into a data and technology-enabled services enterprise. Today, PSG’s proprietary Artemetrx platform, informed by the industry’s most trusted advisors, helps employers and health plans drive maximum value from their drug benefit spend by reducing pharmacy investment and improving patient outcomes.
In 2012, PSG launched its 340B division with 340B Link, a comprehensive suite of solutions used by eligible hospitals, health systems and health centers to manage compliance and capture 340B drug cost savings on outpatient prescriptions filled through the hospital pharmacy or a contracted pharmacy partner.
Today, PSG employs more than 200 team members and serves hundreds of customers throughout the US. The company ranks #65 on the Dallas 100 list of fastest-growing, privately-held companies in the Dallas Metroplex and was recently named to the Inc 5000 list of fastest-growing private companies in America for the third year in a row.